Table of Content

1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Cell Free Systems
3.3. Overview of Cell Free Biomanufacturing
3.3.1. Advantages
3.3.2. Challenges
3.4. Applications of Cell Free Biomanufacturing
3.4.1. Applications in Healthcare Domain
3.4.2. Applications in Other Domains
3.5. Future Perspectives

4. MARKET LANDSCAPE: CELL FREE EXPRESSION SERVICE PROVIDERS
4.1. Chapter Overview
4.2. Cell Free Expression Service Providers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Type of Cell Free Expression Service(s) Offered
4.2.5. Analysis by Type of Associated Service(s) Offered
4.2.6. Analysis by Type of Host Organism
4.2.7. Analysis by Type of Product(s) Synthesized
4.2.8. Analysis by Scale of Operation
4.2.9. Analysis by Type of Industry Served

5. MARKET LANDSCAPE: CELL FREE EXPRESSION KITS
5.1. Chapter Overview
5.2. Cell Free Expression Kits: Overall Market Landscape
5.2.1. Analysis by Type of Cell Free System
5.2.2. Analysis by Type of Host Organism
5.2.3. Analysis by Type of Expression Method
5.2.4. Analysis by Type of Product(s) Synthesized
5.2.5. Analysis by Type of Template(s) Used
5.2.6. Analysis by Type of Compatible Promoter(s)
5.2.7. Analysis by Type of Reaction Format
5.2.8. Analysis by Yield of Positive Control
5.2.9. Analysis by Reaction Volume
5.2.10. Analysis by Reaction Temperature
5.2.11. Analysis by Incubation Time
5.2.12. Analysis by Number of Reactions per Kit
5.2.13. Analysis by Kit Price
5.3. Cell Free Expression Kit Providers Landscape
5.3.1. Analysis by Year of Establishment
5.3.2. Analysis by Company Size
5.3.3. Analysis by Location of Headquarters
5.3.4. Most Active Players: Analysis by Number of Cell free Expression Kits Developed

6. CELL FREE EXPRESSION SERVICE PROVIDERS: COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Assumptions and Key Parameters
6.3. Methodology
6.4. Company Competitiveness Analysis: Cell Free Expression Service Providers
6.4.1. Company Competitiveness Analysis: Small Service Providers
6.4.2. Company Competitiveness Analysis: Mid-sized Service Providers
6.4.3. Company Competitiveness Analysis: Large and Very Service Providers

7. CELL FREE EXPRESSION KITS: PRODUCT COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Assumptions and Key Parameters
7.3. Methodology
7.4. Product Competitiveness Analysis: Cell Free Expression Kits
7.4.1. Product Competitiveness Analysis: Cell Free Expression Kits Developed by Players based in North America
7.4.2. Product Competitiveness Analysis: Cell Free Expression Kits Developed by Players based in Europe
7.4.3. Product Competitiveness Analysis: Cell Free Expression Kits Developed by Players based in Asia-Pacific and Rest of the World

8. COMPANY PROFILES: CELL FREE EXPRESSION SERVICE PROVIDERS
8.1. Chapter Overview
8.2. BioLinker
8.2.1. Company Overview
8.2.2. Cell Free Expression Service Portfolio
8.2.3. Recent Developments and Future Outlook
8.3. CUSABIO
8.3.1. Company Overview
8.3.2. Cell Free Expression Service Portfolio
8.3.3. Recent Developments and Future Outlook
8.4. LenioBio
8.4.1. Company Overview
8.4.2. Cell Free Expression Service Portfolio
8.4.3. Recent Developments and Future Outlook
8.5. Touchlight
8.5.1. Company Overview
8.5.2. Cell Free Expression Service Portfolio
8.5.3. Recent Developments and Future Outlook

9. COMPANY PROFILES: CELL FREE EXPRESSION KIT PROVIDERS
9.1. Chapter Overview
9.2. biotechrabbit
9.2.1. Company Overview
9.2.2. Cell Free Expression Kit Portfolio
9.2.3 Recent Developments and Future Outlook
9.3. CellFree Sciences
9.3.1. Company Overview
9.3.2. Cell Free Expression Kit Portfolio
9.3.3 Recent Developments and Future Outlook
9.4. Creative Biolabs
9.4.1. Company Overview
9.4.2. Cell Free Expression Kit Portfolio
9.4.3 Recent Developments and Future Outlook
9.5. Diacel Arbor Biosciences
9.5.1. Company Overview
9.5.2. Cell Free Expression Kit Portfolio
9.5.3 Recent Developments and Future Outlook
9.6. Promega
9.6.1. Company Overview
9.6.2. Cell Free Expression Kit Portfolio
9.6.3 Recent Developments and Future Outlook
9.7. Thermo Fisher Scientific
9.7.1. Company Overview
9.7.2. Cell Free Expression Kit Portfolio
9.7.3. Recent Developments and Future Outlook

10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Cell free System: Partnerships and Collaborations
10.3.1 Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Year and Type of Partnership
10.3.4. Analysis by Focus Area
10.3.5. Analysis by Type of Partner
10.3.6. Most Active Players: Analysis by Number of Partnerships
10.3.7. Local and International Agreements
10.3.8. Intercontinental and Intracontinental Agreements

11. FUNDING AND INVESTMENT ANALYSIS
11.1. Chapter Overview
11.2. Types of Funding
11.3. Cell free System: Funding and Investment Analysis
11.3.1. Analysis of Instances by Year of Investment
11.3.2. Analysis of Amount Invested by Year of Investment
11.3.3. Analysis of Instances by Type of Funding
11.3.4. Analysis of Amount Invested by Type of Funding
11.3.5. Analysis by Instances of Type of Investor
11.3.6. Most Active Players: Analysis by Number of Instances
11.3.7. Most Active Players: Analysis by Amount Invested
11.3.8. Analysis of Amount Invested by Geography
11.3.8.1. Analysis by Region
11.3.8.2. Analysis by Country

12. PATENT ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Cell free System: Patent Analysis
12.3.1. Analysis by Patent Publication Year
12.3.2. Analysis by Patent Application Year
12.3.3. Analysis by Annual Number of Granted Patents and Patent Applications
12.3.4. Analysis by Patent Jurisdiction
12.3.5. Analysis by CPC Symbols
12.3.6. Analysis by Type of Applicant
12.3.7. Leading Industry Players: Analysis by Number of Patents
12.3.8. Leading Non-Industry Players: Analysis by Number of Patents
12.3.9. Leading Individual Assignees: Analysis by Number of Patents
12.4. Cell free System: Patent Benchmarking Analysis
12.4.1. Analysis by Patent Characteristics
12.5. Cell free System: Patent Valuation
12.6. Leading Patents: Analysis by Number of Citations
13. MARKET FORECAST AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Key Assumptions and Forecast Methodology
13.3. Global Cell Free Expression Market, 2023-2035
13.3.1. Cell Free Expression Market: Distribution by Type of Cell Free System, 2023 and 2035
13.3.1.1. Cell Free Expression Market for Crude Cell Lysate-based Systems, 2023-2035
13.3.1.2. Cell Free Expression Market for Reconstituted Systems, 2023-2035
13.3.2. Cell Free Expression Market: Distribution by Type of Host Organism, 2023 and 2035
13.3.2.1. Cell Free Expression Market for Microbial Cell Free Expression Systems, 2023-2035
13.3.2.2. Cell Free Expression Market for Mammalian Cell Free Expression Systems, 2023-2035
13.3.2.3. Cell Free Expression Market for Plant-based Cell Free Expression Systems, 2023-2035
13.3.2.4. Cell Free Expression Market for Other Cell Free Expression Systems, 2023-2035
13.3.3. Cell Free Expression Market: Distribution by Type of Expression Method, 2023 and 2035
13.3.3.1. Cell Free Expression Market for Coupled Transcription and Translation Method, 2023-2035
13.3.3.2. Cell Free Expression Market for Translation Method, 2023-2035
13.3.4. Cell Free Expression Market: Distribution by End-User, 2023 and 2035
13.3.4.1. Cell Free Expression Market for Pharmaceutical and Biotechnology Companies, 2023-2035
13.3.4.2. Cell Free Expression Market for Academic and Research Institutes, 2023-2035
13.3.4.3. Cell Free Expression Market for Other End-Users, 2023-2035
13.3.5. Cell Free Expression Market: Distribution by Key Geographical Regions, 2023 and 2035
13.3.5.1. Cell Free Expression Market in North America, 2023-2035
13.3.5.2. Cell Free Expression Market in Europe, 2023-2035
13.3.5.3. Cell Free Expression Market in Asia-Pacific, 2023-2035
13.3.5.4. Cell Free Expression Market in Rest of the World, 2023-2035
14. EXECUTIVE INSIGHTS
14.1. Chapter Overview
14.2. Gene Frontier
14.2.1. Company Snapshot
14.2.2. Interview Transcript: Takashi Ebihara, Chief Operational Officer
14.3. LenioBio
14.3.1. Company Snapshot
14.3.2. Interview Transcript: Remberto Martis, Founder and Chief Executive Officer

15. CONCLUDING REMARKS

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS